Saxenda Side Effects: Withdrawal and Discontinuation Syndrome Explained

Does Saxenda cause withdrawal?

Saxenda is a GLP-1 receptor agonist injected once daily under the skin, approved with a reduced-calorie diet and more physical activity for adults with obesity or overweight with a weight-related condition, and for adolescents aged 12 and older with body weight above 60 kg and obesity [1]. Its label covers what happens during treatment: nausea, vomiting, diarrhea, constipation, gallbladder disease, pancreatitis, a small rise in heart rate, and hypoglycemia when it is combined with insulin or a sulfonylurea [1]. Withdrawal or dependence is not among the listed warnings, and the dosing section describes an escalation schedule but no taper [1].

The label describes GLP-1 as a physiological regulator of appetite and calorie intake, notes that GLP-1 receptors are present in brain areas involved in appetite regulation, and states that liraglutide delays gastric emptying [1].

How fast does liraglutide leave the body?

The label gives a plasma half-life of about 13 hours and peak levels roughly 11 hours after an injection, which is why the product is dosed once daily [1].

The label's re-entry instruction is written for gaps in dosing: if more than 3 days have passed since the last Saxenda dose, restart at 0.6 mg daily and follow the escalation schedule, to reduce the risk of gastrointestinal adverse reactions associated with reinitiating treatment [1]. For a missed dose, the label says to resume with the next scheduled daily dose and not to double up [1].

What the label says about stopping

The label gives more than one route to stopping treatment:

• Adults who cannot tolerate the 3 mg dose: the label says to discontinue Saxenda; lower doses are for titration only [1]. For pediatric patients who do not tolerate 3 mg, the label allows a reduction to 2.4 mg daily [1].
• Weight check at 16 weeks in adults: the label says to discontinue Saxenda if at least 4% of baseline body weight has not been lost [1].
• Suspected acute pancreatitis: the label says to discontinue Saxenda [1].
• Pregnancy recognized: the label says to discontinue Saxenda [1].
• Serious hypersensitivity reaction: the label says to discontinue Saxenda and other suspect medications [1].

The label's dose schedule runs upward: 0.6 mg in week 1, then 1.2, 1.8, 2.4, and 3 mg from week 5 onward [1].

What happens to weight after stopping?

The after-stopping outcome the trials speak to most directly comes from the adolescent trial, which had a 56-week treatment period followed by 26 weeks of follow-up: weight regain after treatment ended was greater with liraglutide than with placebo [2].

The adult results below measure weight change during treatment. In SCALE Maintenance, 422 adults who had already lost at least 5% of body weight on a low-calorie diet were randomized to liraglutide 3 mg or placebo for 56 weeks on top of diet and exercise counselling [4]. From randomization to week 56, weight fell a further 6.2% with liraglutide and 0.2% with placebo, and 81.4% versus 48.9% maintained the 5% loss achieved during the diet run-in [4].

In SCALE Obesity and Prediabetes, 3,731 adults without type 2 diabetes were randomized 2:1 to liraglutide 3 mg or placebo for 56 weeks [5]. Mean weight loss at week 56 was 8.4 kg with liraglutide versus 2.8 kg with placebo (last observation carried forward), a difference of -5.6 kg, and 63.2% versus 27.1% lost at least 5% of body weight [5].

What are the gastrointestinal effects during treatment?

In the adult trials (3,384 on Saxenda versus 1,941 on placebo), nausea occurred in 39.3% versus 13.8%, diarrhea in 20.9% versus 9.9%, constipation in 19.4% versus 8.5% and vomiting in 15.7% versus 3.9%; about 68% versus 39% reported any GI disorder, and nausea declined as treatment continued [1]. Adverse reactions led to discontinuation in 9.8% versus 4.3%, most often nausea (2.9% versus 0.2%), vomiting (1.7% versus less than 0.1%) and diarrhea (1.4% versus 0%) [1].

Mood and the suicidal thoughts warning that was removed

This is the part of the Saxenda label that changed most recently. FDA issued a drug safety communication on 13 January 2026 asking the makers of Saxenda, Wegovy and Zepbound to remove suicidal behavior and ideation language from their labeling, after a review that included a meta-analysis of 91 placebo-controlled GLP-1 receptor agonist trials (107,910 patients) and a claims cohort of 2,243,138 new users; FDA stated it found no increased risk of suicidal ideation or behavior with these medicines [3].

The Saxenda label dated 26 January 2024 listed a Warnings and Precautions item saying to monitor for depression or suicidal thoughts and to discontinue Saxenda if symptoms develop [6]. The current label, effective 25 February 2026, has no such section [1]. Depression does still appear in the pediatric trial table, at 4% with Saxenda versus 2.4% with placebo [1].

Pregnancy, adolescents and type 2 diabetes

Pregnancy. The current label says Saxenda should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, that weight loss offers no benefit in pregnancy, and that Saxenda should be discontinued when pregnancy is recognized; this is not a formal contraindication [1].

Adolescents. The indication starts at age 12 with body weight above 60 kg and obesity [1]. In the 56-week trial of 251 adolescents, adverse events led to discontinuation in 10.4% on liraglutide versus 0% on placebo, and one suicide occurred in the liraglutide group, judged by the investigator as unlikely related to treatment [2].

Type 2 diabetes. Saxenda is not indicated for glycemic control [1]. The label warns that hypoglycemia can occur when it is used with insulin or an insulin secretagogue and that the risk may be lowered by reducing the dose of those drugs; among adults with type 2 diabetes taking a sulfonylurea, glucose below 54 mg/dL occurred in 28.2% on Saxenda versus 12.7% on placebo, with sulfonylurea doses cut by 50% at the start of the trial [1].